{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:34:26Z","timestamp":1782189266431,"version":"3.54.5"},"reference-count":19,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2025,6,23]]},"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1136\/ejhpharm-2024-004378","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T13:20:25Z","timestamp":1751376025000},"page":"166-170","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Patient experience in healthcare interventions: PROM and PREM evaluation in patients with multiple sclerosis after switching administration route of natalizumab"],"prefix":"10.1136","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6093-6201","authenticated-orcid":false,"given":"Cristina","family":"Fern\u00e1ndez-Cuerva","sequence":"first","affiliation":[{"name":"Pharmacy Department, Hospital Regional Universitario de Malaga, Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aranzazu","family":"Linares-Alarcon","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Regional Universitario de Malaga, Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Morales Lara","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Regional Universitario de Malaga, Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7337-8384","authenticated-orcid":false,"given":"Ana Maria","family":"Alonso Torres","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Regional Universitario de Malaga, Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Reyes-Garrido","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Regional Universitario de Malaga, Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Urbaneja","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Regional Universitario de Malaga, Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Sanchez-Guijo Benavente","sequence":"additional","affiliation":[{"name":"Neurology Department, Hospital Regional Universitario de Malaga, Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2026022302200634000_33.2.166.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1401483"},{"key":"2026022302200634000_33.2.166.2","unstructured":"Multiple Sclerosis International Federation . Number of people with MS. Atlas of MS. 2024. Available: https:\/\/www.atlasofms.org\/map\/global\/epidemiology\/number-of-people-with-ms [Accessed 14 Mar 2024]."},{"key":"2026022302200634000_33.2.166.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2020.05.049"},{"key":"2026022302200634000_33.2.166.4","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2023-0016","article-title":"Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis","volume":"12","author":"Samjoo","year":"2023","journal-title":"J Comp Eff Res"},{"key":"2026022302200634000_33.2.166.5","unstructured":"CIMA . Ficha t\u00e9nica de tysabri 300 mg concentrado para soluci\u00f3n para perfusi\u00f3n. Agencia espa\u00f1ola del medicamento. 2024. Available: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/06346001\/FT_06346001.html [Accessed 14 Apr 2024]."},{"key":"2026022302200634000_33.2.166.6","unstructured":"CIMA . Ficha t\u00e9nica de tysabri 150 mg soluci\u00f3n inyectable para jeringa precargada. Agencia espa\u00f1ola del medicamento. Available: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/106346002\/FT_106346002.html [Accessed 29 Apr 2025]."},{"key":"2026022302200634000_33.2.166.7","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/jcph.707","article-title":"A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis","volume":"56","author":"Plavina","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"2026022302200634000_33.2.166.8","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211003020"},{"key":"2026022302200634000_33.2.166.9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s41669-023-00394-2","article-title":"Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain","volume":"7","author":"Alonso Torres","year":"2023","journal-title":"Pharmacoecon Open"},{"key":"2026022302200634000_33.2.166.10","first-page":"37","article-title":"Outcome and patient-reported experience measurement instruments: Guidelines and tools to identify and select the most suitable","volume":"32","author":"Zabaleta-Del-Olmo","year":"2021","journal-title":"Enferm Intensiva (Engl Ed)"},{"key":"2026022302200634000_33.2.166.11","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-4-79","article-title":"Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance","volume":"4","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"2026022302200634000_33.2.166.12","doi-asserted-by":"crossref","first-page":"111017","DOI":"10.1016\/j.drugalcdep.2023.111017","article-title":"Patient Reported Outcome and Experience Measures (PROMs and PREMs) in substance use disorder treatment services: A scoping review","volume":"253","author":"Migchels","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"2026022302200634000_33.2.166.13","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.msard.2018.12.021","article-title":"Benefit evaluation in multiple sclerosis relapse treatment from the patients\u2019 perspective - Development and validation of a new questionnaire","volume":"28","author":"Beckmann","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2026022302200634000_33.2.166.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2005.00568.x"},{"key":"2026022302200634000_33.2.166.15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw685"},{"key":"2026022302200634000_33.2.166.16","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2147\/PPA.S108489","article-title":"Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab","volume":"10","author":"Theodore-Oklota","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"2026022302200634000_33.2.166.17","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241241382","article-title":"Real-world evidence and patient preference for subcutaneous versus intravenous natalizumab in the treatment of relapsing-remitting multiple sclerosis - initial results from the observational SISTER study","volume":"17","author":"Gold","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"2026022302200634000_33.2.166.18","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1007\/s12325-019-01101-6","article-title":"Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site","volume":"36","author":"Usach","year":"2019","journal-title":"Adv Ther"},{"key":"2026022302200634000_33.2.166.19","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2147\/PPA.S303279","article-title":"Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review","volume":"15","author":"Overton","year":"2021","journal-title":"Patient Prefer Adherence"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2024-004378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:20:47Z","timestamp":1771842047000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2024-004378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,23]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/ejhpharm-2024-004378"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2024-004378","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}